Navigation Links
Jeffrey Epstein, New York Philanthropist, Funds Pioneering Cancer Metastasis Research at Mount Sinai
Date:4/13/2013

NEW YORK, April 13, 2013 /PRNewswire/ -- It is well known that once a tumor metastasizes into the blood stream, the odds of combatting the cancer decline sharply. Early removal of tumors therefore, is an essential way to improve survival. In pivotal research conducted at Mount Sinai Hospital in New York City, surgeon Dr. Jess Ting, breast oncologist, Dr. Kerin Adelson and molecular biologist, Dr. Doris Germain , are looking at how metastasis is not necessarily intrinsic to the tumor but to its micro-environment. The shift in focus is critical Dr. Ting explains because it will be an effective way to identify and stratify those at high risk of metastasis after surgery.

Dr. Ting's research also received an essential financial boost from Jeffrey Epstein, the science philanthropist and financier, who established the Program for Evolutionary Dynamics at Harvard University in 2003.

To obtain a breast tumor's micro-environment, Dr. Ting and his team are using the unique approach of studying fluid emitted from a post-surgery wound site. To date, clinical analysis of a cancer's environment has been the blood, a rich source of disease-related biomarkers. However, blood's complex composition, amongst other factors, is a major challenge for biomarker assays. Other body fluids, including urine, cerebrospina, bronchoalveolar lavage, synovial, amniotic, seminal plasma and interstitial fluids are also rich in disease biomarkers. However, these fluids are only informative in advanced metastatic cancer patients and so their prognostic value in term of disease progression is limited.

Dr. Ting's team saw that wound fluid (emitted from a draining tube), contains all the proteins, growth factors and cytokines that are secreted by the cells around the cancer and is an ideal way of studying the microenvironment in vivo. Furthermore, wound fluid from a breast cancer patient often has the tremendous advantage of having an exact control specimen since the non-cancerous breast is often removed as a precaution and wound fluid from that breast can be compared.

Over the last year, Dr. Ting and his team have found distinct differences between cancerous wound fluid and non-cancerous both in test tubes and in mice. It is these differences that will be critical biomarkers in determining risk of future metastasis.

"Identifying post-surgery patients at high risk of metastasis is vital," Jeffrey Epstein remarked. "It will be a key factor in prioritizing them for constant vigilance."

The Jeffrey Epstein VI Foundation, funds science research around the world. Jeffrey Epstein is a former member of the Trilateral Commission, the Council on Foreign Relations and the New York Academy of Science. He is actively involved in the Santa Fe Institute, the Theoretical Biology Initiative at the Institute for Advanced Study in Princeton and sits on the Mind, Brain and Behavior Advisory Committee at Harvard University.


'/>"/>
SOURCE Jeffrey Epstein VI Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Largest Private Funder Of Melanoma Research Receives Vital Support From Activist Jeffrey Epstein
2. Jeffrey Modell Foundation Opens Diagnostic Center for Primary Immunodeficiencies at Midwest Immunology Clinic
3. Financier Jeffrey Epstein And Mount Sinai Hospital Support 3D Mammograms For Breast Cancer
4. AgaMatrix elects Jeffrey B. Kindler to its Board of Directors
5. Jeffrey Wasserstein Joins Greenhill as Managing Director Focused on the Pharmaceutical Sector
6. French Regulator Lina Ertle, FDAs Jeffrey Baker and Patrick Swann Confirmed Speakers at 2013 PDA/FDA Process Validation Workshop
7. IDEXX Laboratories Names Jeffrey Fiarman Executive Vice President and General Counsel
8. Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler
9. OICR funds Fluorinov Pharma Inc. to further develop its novel drug for the treatment of blood cancers
10. Community Foundation Announces $2.6 Million In Grants From Centinela Medical Funds
11. Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):